These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. NICE TA170: Rivaroxaban for prevention of VTE post hip or knee surgeryĭrugs designated amber are suitable for shared care arrangements under a shared care protocol. NICE TA157: Dabigatran for prophylaxis of VTE post hip or knee surgery NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
NICE TA261: Rivaroxaban for treatment of DVT NICE TA354: Edoxaban for treating and preventing DVT/PE NICE TA327: Dabigatran for the treatment and secondary prevention of DVT/PE NICE TA341: Apixaban for the treatment and secondary prevention of DVT/PE GMMMG Prescribing Support for Novel Oral Anticoagulants (NOACs) NICE CG144: Venous thromboembolic diseases NICE TA249: Dabigatran for Stroke prevention in AF This may be used on the advice of a haematologist only - see PAT guideline: Management of Bleeding in Patients Receiving Anti-thrombotic Agents. Praxbind ® (idarucizumab) is a specific reversal agent for dabigatran. NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275) NICE TA355: Edoxaban for stroke prevention in AF NCA Interim Position on the use of Edoxaban QRG GMMMG Prescribing Support for Direct Oral Anticoagulants (DOACs) UKMI Q&A: IM injections in warfarin patients MHRA Safety Alert: Calciphylaxis with Warfarin NCA Guideline: Management of bleeding in patients receiving anti-thrombotic agents NCA Guideline for the Management of Oral Anticoagulation in patients with Atrial Fibrillation Northern Care Alliance NHS Group NES Formularyįormulary Chapter 2: Cardiovascular system - Full Chapterĭrug Safety Advice 2013 (new oral anticoagulants) Northern Care Alliance NHS Group Formulary
0 kommentar(er)
